
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular Inc. demonstrated notable financial performance, with gross margin expanding by 110 basis points year-over-year to 70%, attributed to increased average selling prices, manufacturing efficiencies, and a favorable product mix. Revenue for the quarter rose by 15%, driven by strong contributions from the catheter category and significant growth in international sales, alongside an operating income increase of 12% to $16.1 million, resulting in an operating margin of 25%. The company anticipates continued momentum, projecting a year-end gross margin of 69.7% and operating income growth of 17%, reinforcing a positive outlook for strong sales growth and expanding margins.
Bears say
LeMaitre Vascular is facing a declining operating margin, expected to decrease from 25% to 24% due to seasonal variations, indicating potential challenges in maintaining profitability. The reduction in the target number of sales representatives from 170 to 165 could signal difficulties in driving sales growth, reflecting a cautious outlook on revenue generation. Additionally, a notable decrease in R&D spending to 6% of revenue highlights concerns about the firm's commitment to innovation amidst competitive pressures and regulatory challenges, which could adversely affect future financial performance.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares